BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34739698)

  • 21. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
    Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
    Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Expression of serum human epididymis protein 4 in epithelial ovarian cancer and its correlation with prognosis].
    Zheng H; Gao YN; Gao WJ; Gao M; Yan X
    Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):445-9. PubMed ID: 24119905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
    Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of Lewis y antigen and integrin αv, β3 in ovarian cancer and their relationship with chemotherapeutic drug resistance.
    Gao J; Hu Z; Liu D; Liu J; Liu C; Hou R; Gao S; Zhang D; Zhang S; Lin B
    J Exp Clin Cancer Res; 2013 Jun; 32(1):36. PubMed ID: 23725446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility.
    Lu R; Sun X; Xiao R; Zhou L; Gao X; Guo L
    Biochem Biophys Res Commun; 2012 Mar; 419(2):274-80. PubMed ID: 22342977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Carpén O; Matomäki J; Oksa S; Virtanen J; Grénman S
    Tumour Biol; 2014 Dec; 35(12):12389-95. PubMed ID: 25190018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting and neutralizing human epididymis protein 4 by novel nanobodies to suppress ovarian cancer cells and attenuate cisplatin resistance.
    Yu J; Guo Y; Gu Y; Li F; Song H; Nian R; Fan X; Liu W
    Int J Biol Macromol; 2022 Feb; 199():298-306. PubMed ID: 35016970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.
    Li F; Tie R; Chang K; Wang F; Deng S; Lu W; Yu L; Chen M
    BMC Cancer; 2012 Jun; 12():258. PubMed ID: 22712526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells.
    Wang H; Zhu L; Gao J; Hu Z; Lin B
    Oncol Rep; 2015 Jan; 33(1):403-12. PubMed ID: 25354091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients.
    Steffensen KD; Waldstrøm M; Brandslund I; Petzold M; Jakobsen A
    Int J Gynecol Cancer; 2012 Nov; 22(9):1474-82. PubMed ID: 23095772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].
    Shipeng G; Yongning C; Yadi Z; Chanyuan LI; Qifan J
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec; 39(12):1393-1401. PubMed ID: 31907150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer.
    Manganaro L; Michienzi S; Vinci V; Falzarano R; Saldari M; Granato T; Viggiani V; Frati L; Anastasi E
    Oncol Rep; 2013 Nov; 30(5):2481-7. PubMed ID: 23970060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human epididymis protein 4 in association with Annexin II promotes invasion and metastasis of ovarian cancer cells.
    Zhuang H; Tan M; Liu J; Hu Z; Liu D; Gao J; Zhu L; Lin B
    Mol Cancer; 2014 Nov; 13():243. PubMed ID: 25362534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
    Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
    Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human epididymis protein 4 promotes P‑glycoprotein‑mediated chemoresistance in ovarian cancer cells through interactions with Annexin II.
    Liu Q; Liu DW; Zheng MJ; Deng L; Wang HM; Jin S; Liu JJ; Hao YY; Zhu LC; Lin B
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33955501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.
    Fujiwara H; Suzuki M; Takeshima N; Takizawa K; Kimura E; Nakanishi T; Yamada K; Takano H; Sasaki H; Koyama K; Ochiai K
    Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer.
    Chen WT; Gao X; Han XD; Zheng H; Guo L; Lu RQ
    Asian Pac J Cancer Prev; 2014; 15(1):101-5. PubMed ID: 24528007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer.
    Kong SY; Han MH; Yoo HJ; Hwang JH; Lim MC; Seo SS; Yoo CW; Kim JH; Park SY; Kang S
    Ann Surg Oncol; 2012 May; 19(5):1707-12. PubMed ID: 21833668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
    Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
    Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.